Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Amifostine 9Radiotherapy 6Cisplatin 5Paclitaxel 4Etoposide 3Cyclophosphamide 3Carboplatin 3sargramostim 1lometrexol 1denileukin diftitox 1Thiotepa 1Taxes 1Silymarin 1Radiation 1Pyridostigmine Bromide 1Phenobarbital 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Irinotecan 1Ifosfamide 1Idarubicin 1Folic Acid 1Filgrastim 1Fibroblast Growth Factor 7 1Docetaxel 1Dexamethasone 1Cytarabine 1Cyclosporine 1Bleomycin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Drug-Related Side Effects and Adverse Reactions × Silymarin × Clear all
NCT00055718 2013-12-18

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡